Dermatological Drugs Market Report 2026

The dermatological drugs market size has grown strongly in recent years. It will grow from $21.98 billion in 2025 to $24.08 billion in 2026 at a compound annual growth rate (CAGR) of 9.6%. The growth in the historic period can be attributed to high prevalence of skin disorders, reliance on topical steroids, hospital-based dermatology, growing cosmetic awareness, aging population.

The dermatological drugs market size is expected to see strong growth in the next few years. It will grow to $34.31 billion in 2030 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to advancements in biologics, growth of personalized dermatology, increasing chronic skin disease burden, expanding dermatology clinics, innovation in formulations. Major trends in the forecast period include rising use of biologic dermatology drugs, growth of targeted skin therapies, expansion of topical treatment options, increased focus on chronic skin conditions, growth of prescription dermatology.

The growing demand for cosmetic dermatology procedures is expected to drive the expansion of the dermatological drugs market in the coming years. Cosmetic dermatology is a specialized field that focuses on improving physical appearance through a range of non-surgical treatments and procedures. Demand for cosmetic dermatology is increasing due to greater consumer awareness of aesthetic solutions, continuous advancements in skincare technologies, and a rising preference for minimally invasive procedures to enhance appearance and address signs of aging. The expanding use of cosmetic dermatology treatments, including anti-aging and skin rejuvenation procedures, is encouraging the development of advanced dermatological drugs that provide safe, effective, and minimally invasive treatment options. For instance, in June 2024, according to the International Society of Aesthetic Plastic Surgery (ISAPS), a global nonprofit scientific organization representing board-certified plastic surgeons, the total number of surgical and non-surgical aesthetic procedures rose by 3.4% in 2023, reaching 34.9 million worldwide compared to the previous year. As a result, the increasing adoption of cosmetic dermatology procedures is contributing to the growth of the dermatological drugs market.

Major companies operating in the dermatological drugs market are increasingly prioritizing the development of biologic therapies to treat chronic skin conditions such as psoriasis, atopic dermatitis, and hidradenitis suppurativa. Biologic treatments work by targeting specific immune pathways, providing more effective and longer-lasting benefits compared to conventional treatment options. For example, in September 2024, Eli Lilly and Company, a US-based pharmaceutical firm, received approval for Ebglyss (lebrikizumab), a targeted interleukin-13 (IL-13) inhibitor, for the treatment of moderate-to-severe atopic dermatitis in adults and children aged 12 years and older. This approval represents a notable advancement by introducing a new biologic therapy for patients who have not achieved sufficient symptom control with topical treatments. By addressing unmet clinical needs, Ebglyss is intended to enhance patient quality of life by reducing severe itching and skin inflammation associated with moderate-to-severe atopic dermatitis.

In September 2024, Organon, a US-based pharmaceutical company, acquired Dermavant Sciences Ltd. for $1.2 billion. Through this acquisition, Organon added Dermavant’s lead product, VTAMA (tapinarof) cream, 1%, to its portfolio. VTAMA is a non-steroidal topical therapy approved by the US Food and Drug Administration (FDA) for the treatment of mild, moderate, and severe plaque psoriasis in adults. Dermavant Sciences Ltd. is a US-based immunodermatology company focused on the development and commercialization of innovative dermatology treatments.

Major companies operating in the dermatological drugs market are Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Bayer AG, AstraZeneca plc, Novartis AG, GlaxoSmithKline Plc, Eli Lilly and Company, Amgen Inc., Bausch Health Companies Inc., Organon International, Galderma, Incyte Corporation, Glenmark Pharmaceuticals Ltd., Mayne Pharma Group Limited, Dermavant Sciences Inc., Taro Pharmaceutical Industries Ltd., Biofrontera AG, Almirall SA, UCB SA, LEO Pharma A/S, Dermira Inc.

North America was the largest region in the dermatological drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the dermatological drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the dermatological drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the dermatological drugs market by increasing costs of imported active pharmaceutical ingredients, excipients, and packaging materials. Hospitals and pharmacies in North America and Europe are most affected due to dependence on imported drugs, while Asia-Pacific faces higher manufacturing input costs. These tariffs are increasing drug prices. However, they are encouraging domestic pharmaceutical production.

The dermatological drugs market research report is one of a series of new reports that provides dermatological drugs market statistics, including dermatological drugs industry global market size, regional shares, competitors with a dermatological drugs market share, detailed dermatological drugs market segments, market trends and opportunities, and any further data you may need to thrive in the dermatological drugs industry. This dermatological drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Dermatological drugs are medications developed to treat conditions affecting the skin, hair, and nails by reducing inflammation, controlling infections, or alleviating symptoms such as itching and redness. These drugs are essential in dermatology for managing both common and severe skin disorders, thereby improving patient comfort and overall quality of life.

The primary drug classes in the dermatological drugs market include corticosteroids, retinoids, antibiotics, antifungals, calcineurin inhibitors, and others. Corticosteroids are a group of steroid hormones that help reduce inflammation and suppress immune responses by replicating the effects of cortisol, a naturally occurring hormone produced by the adrenal glands. These drugs are administered through various routes, including topical, oral, and parenteral administration, and are used to treat multiple indications such as acne, psoriasis, rosacea, alopecia, and others. Distribution channels for dermatological drugs include hospital pharmacies, retail pharmacies, and others.

The dermatological drugs market consists of sales of creams, ointments, gels, and lotions. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.